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Abstract
Gestational diabetes is generally associated with a higher
morbidity and mortality for both the mother and child.
Aims: The study aims to assess the outcome indicators of
women suffering gestational diabetes and compare these to the
remaining obstetric population.
Research Design and Methods: Outcome indicators of
women diagnosed during pregnancy as suffering from diabetes
(GDM (defined as a 2-hour post-load blood glucose of >=8.6
mmol/l) n=297) were compared to the parameters of women
with a presumed normal carbohydrate metabolism (n = 16059).
Results: The incidence of gestational diabetes in the
Maltese pregnant population is 1.81 % of total maternities.
Women with GDM showed themselves to be at a significantly
increased risk of developing hypertensive disorders during
pregnancy and to require delivery by caesarean section. They
were more likely to require intervention by induction of labour,
while the delivery was commonly complicated by shoulder
dystocia. The infants born to GDM women were more likely to
be macrosomic or preterm and have a low Apgar score at birth
and suffer from respiratory distress. The infants did not show a
greater predisposition to be of low birth weight.
Conclusion: It would appear that gestational diabetes
remains a high-risk situation that increases maternal and infant
morbidity in spite of the modern management options.
Introduction
Diabetes in pregnancy can present itself in two clinical
situations. Pregnancy can occur in a previously existing diabetic
(Pre-existing DM), or it can appear de novo during pregnancy
(Gestational DM). Disorders of carbohydrate metabolism, i.e.,
Diabetes Mellitus (DM) and Impaired Glucose Tolerance (IGT),
remain one of the most important public health problems in
the Maltese population, which was shown in the early 1980s to
have a prevalence rate in the female population of 15.2%. The
condition is commoner in the elderly population so that the
prevalence on women in the reproductive age amounted to only
2.2%. 1  The high prevalence rates are reflected in the pregnant
population.2  The present study set out to assess the morto-
morbidity of mothers and their infants in the presence of
gestational diabetes.
Material & Methods
The study reviewed the medical data records of all women
delivering in the Maltese Islands during 1999-2002 (n = 16413
maternities resulting in 16641 births). The medical data was
made available by the National Obstetric Information System
managed by the Department of Health Information (Malta).
This database has been previously described.3 Information
pertaining to the incidence of congenital malformations was
made available from the Malta Congenital Anomalies Register4
for years 1999-2001 (total infants born = 12494, inclusive 280
infants of women with previously-existing DM (pre-DM) and
GDM). During the three-year period three cases of congenital
malformations were registered in infants of women with pre-
DM while four cases occurred in infants of GDM women.
The medical records revealed a total of 297 women
diagnosed as suffering from GDM defined as a 2-h post-load
glucose value of >8.6 mmol/l and 57 women who suffered from
a pre-existing form of diabetes mellitus (pre-DM). The outcome
parameters of the women with GDM were compared to the
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parameters of women with presumed or confirmed normal
carbohydrate metabolism (n = 16059). Glucose tolerance testing
is not routinely carried out on all maternities but only in those
women who are considered at particular risk of GDM. During
the study period, 7.2 % of women were thus assessed during
the third trimester of pregnancy.  From prevalence studies, it is
estimated that about 30.7 % of GDM women are thus identified.
The group of patients presumed to have normal carbohydrate
tolerance thus included a small proportion of patients, estimated
as about 4.2 %, with mild degrees of GDM. Statistical
significance was tested using the Chi Square test analysis using
WHO StatCalc statistical package. A probability value of <0.05
was taken to represent a significant correlation.
Results
The incidence of identified GDM during the period 1999-
2002 was 1.81% (Table 1). The age-specific GDM rates appeared
to progressively increase from 0.78 % in the <25 years age group
to 2.14 % in the 25-34 years age group and 4.25% in the >35
years age group (p<0.0001).
GDM has been repeatedly associated with maternal and
infant complications that contribute towards an adverse
maternal and perinatal outcome. GDM was significantly
associated with increased rates of maternal pregnancy-induced
hypertension and pre-eclampsia. These women were also
significantly more likely to require intervention to terminate
the pregnancy by resorting to induction of labour and deliver
by caesarean section (Table 2). While there appeared to be a
progressive increase in multiple pregnancy rates in GDM
women, the differences were not statistically significant. More
than half (62.3% n=185) of the GDM pregnant patients received
structured follow-up, however only 4.7% (n=14) of the GDM
women received insulin supplementation during the course of
their pregnancy. Eight cases (2.7%) had carbohydrate
metabolism abnormalities persisting in the postpartum period.
The altered metabolic state brought on by GDM is associated
with a predisposition to an adverse effect on the neonate. Infants
Table 1: Incidence rates of gestational diabetes
GDM Number % GDM % total
cases maternities
Clinically suspect GDM 28 9.43 0.17
Previous GDM 26 8.75 0.16
Severe GDM 76 25.59 0.46
Mild GDM 167 56.23 1.02
Table 2: Maternal Outcome Parameters
Parameter             Normal metabolism      GDM
Number % Number % P value
Multiple births 210 1.3 8 2.7 0.0751
Maternal PIH/PET 1032 6.4 50 16.8 <0.0001*
Induction of labour 5916 36.8 153 51.5 <0.0001*
Caesarean section 3806 23.7 109 36.7 <0.0001*
Operative vaginal delivery 571 3.6 15 5.1 0.2288
Total 16059 297
Table 3: Infant Outcome parameters
Parameter            Normal metabolism       GDM
Number % Number % P value
Multiple births 210 1.3 8 2.7 0.0751
2nd trimester fetal loss N/A 0 - n/a
Fetal & neonatal loss 159 1.0 2 0.7 0.7980
Low birth weight [<2.5 kg] 1019 6.3 22 7.4 0.5485
Preterm birth [<37 weeks] 1018 6.3 34 11.4 0.002
Infant with RDS 335 2.2 13  4.4 0.015
Macrosomia [>4.0 kg] 927 5.7 37 12.4 <0.0001*
Shoulder dystocia 63 0.4 12 4.0 <0.0001*
Apgar <=6 @ 5 min 188 1.2 7 2.3 0.053
Congenital anomalies 460 [1] 3.8 4 1.3 0.043
Total 16111 299
[1]  based on 1999-2001 data [total infants = 12214]
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born to GDM women show a greater predisposition towards
prematurity, a lowered Apgar score and respiratory distress at
birth. The risks of macrosomia were also statistically increased
in infants born to GDM women, this being associated with a
statistically increased predisposition towards shoulder dystocia.
They did not show a greater predisposition to a low birth weight.
There also did not appear to be any increased risk of antenatal
or neonatal loss (Table 3). An inverse statistical significance
predisposition could be demonstrated in the predisposition
towards the development of major congenital anomalies.
Discussion
Gestational diabetes remains one of the most significant
obstetric complications in the Maltese population affecting
about 1.81 % of the pregnant population. The observed figure is
significantly less than the previously reported prevalence of 5.9%
identified by cross-sectional studies.2  The difference suggests
that the present screening methods in force in Malta are effective
at identifying only about 31 % of expected cases of GDM. The
current screening measure in force is to screen individuals with
a 75-g OGTT whenever these are identified as high-risk on the
basis of their anthropomorphic features, past obstetric and
gynaecological history, family history, and antenatal clinical
indicators.  Since the large majority of severe cases of GDM are
being regularly identified the use of “historical-clinical” risk
criteria is still considered a cost-effective measure in the Maltese
situation.5
There have been major developments in the care of the
pregnant diabetic that has led to a fall in perinatal deaths
attributable to the diabetic problem. However, adverse maternal
and neonatal outcomes are still associated with the pregnant
diabetic woman. The diabetic pregnancy remains fraught with
risks for the mother through the greater predisposition towards
hypertensive disease of pregnancy and pre-eclampsia; and is
furthermore associated with a greater morbidity brought on by
obstetric interventions. The infant of the diabetic mother
similarly suffers from a higher morbidity in the form of a high
birth weight and the associated complications of prematurity.
The inability to equate maternal and infant morbidity of GDM
pregnancies to non-diabetic ones emphasizes the difficulties
faced in attempting to achieve the goal set by the 1989 St.
Vincent’s Declaration that aimed “To achieve a pregnancy
outcome in the diabetic woman that approximates that of the
non-diabetic woman”. 6
Vigilance needs to be maintained to ensure that the
metabolic control of the diabetic patient remains optimal. The
maintenance of optimal metabolic control will remain an
undertaking that requires the joint co-operation of the patient
and the medical team, even in those women who develop GDM,
usually in the third trimester of pregnancy. These women can
often be adequately controlled by strict dietary regimens that
include restriction of refined sugars. Those women with
persisting elevated levels of blood glucose should be suitably
managed by the introduction of hypoglycemic agents. While the
rate of insulin use in Maltese women with GDM appears to be
particularly low when compared to other centers in Europe, the
macrosomia rate in these women appears similar to the reported
median European rates.7  It is possible that insulin, even when
introduced freely, is not the ideal therapeutic option for GDM
where insulin resistance predominates. The use of oral
hypoglycaemic agents, particularly those that act by promoting
peripheral glucose utilization (eg metformin, thiazolidinedione)
or by augmenting insulin secretion (eg sulphonylureas,
meglitinide), should be further investigated since these agents
may provide a therapeutic option that is both safe and effective.
Oral hypoglycaemic agents have been arbitrarily precluded from
use during pregnancy because of the fear of structural or
physiological teratogenesis, a belief that they are ineffective
during pregnancy, and a fear of maternal side-effects. Few
adequate clinical studies have been carried out, but the evidence
seems to suggest that oral hypoglycaemic agents, particularly
those belonging to the second-generation sulphonylurea group
of compounds, have positive therapeutic outcomes in pregnant
women.8-10
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